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A new GTP-binding protein serving as the specific substrate of islet-activating protein (IAP), pertussis toxin, 
was purified from porcine brain membranes as an crjy-heterotrimeric structure. The a-subunit of the purified 
protein (c(&y) had a molecular mass of 40 kDa and differed from that of G, (cQ&) or G, (Q&) previously 
purified from brain tissues. The fragmentation patterns of limited tryptic digestion and immunological 
cross-reactivities among the three oz were different from one another. However, the by-subunit resolved from 
the three IAP substrates similarly inhibited a membrane-bound adenylate cyclase and their /&subunits were 
immunologically indistinguishable from one another. Thus, the c&y is a new IAP substrate protein differ- 
ent from G, or G,, in the cc-subunit only. 
GTP-binding protein; Islet-activating protein; (Pertussis toxin) 
1. INTRODUCTION 
A family of structurally homologous and 
membrane-associated GTP-binding proteins is pre- 
sent in a variety of vertebrate cells. Functionally 
identified and characterized members of this fami- 
ly include the stimulatory (G,) and inhibitory (Gi) 
GTP-binding proteins of the hormone-sensitive 
adenylate cyclase system [l] and the transducin (T) 
of vertebrate retina that communicates between 
light activation of rhodopsin and stimulation of 
cyclic GMP-dependent phosphodiesterase [2]. 
These proteins have been purified from several 
sources as heterotrimers with an &-subunit 
structure. The a-subunits of G,, Gi and T have dif- 
ferent molecular masses, viz. 45, 41 and 39 kDa, 
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respectively, and represent he active species in the 
regulation of the target enzymes [l]. A fourth 
member of this homologous family, termed G,, 
has recently been purified from brain tissues [3-61, 
although its function remains unknown. The cy of 
G, (cu& the molecular mass of which is 39 kDa, as 
well as the LY of Gi (ai) contain a guanine 
nucleotide-binding site and a site for IAP- 
catalyzed ADP-ribosylation. The P-subunits (36 or 
35 kDa) of the four proteins seem to be in- 
distinguishable from each other, and the smallest y 
has been reported to have a molecular mass of 
about 8 kDa [l]. 
Several ines of evidence have been provided for 
a novel role of some GTP-binding proteins in 
Ca’+-related signal transduction [7]. In fact, IAP 
substrate proteins including Gi and G, have been 
found to couple certain types of receptors to 
polyphosphoinositide breakdown in rat mast cells 
[8], guinea pig neutrophils [9,10] and differen- 
tiated human leukemic (HL-60) cells [ 111. 
Moreover, it was reported that muscarinic recep- 
tors were linked to K+ channels in an IAP- 
susceptible fashion in embryonic chick atria1 cells 
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112,131. These reports prompted us to investigate 
the heterogeneities of GTP-binding proteins serv- 
ing as the specific substrate of IAP, since multiple 
IAP substrates eemed to have multiple functions 
in receptor-mediated signal transduction. Here, we 
show that there is a novel IAP substrate in addition 
to Gi and G, in brain tissues. The three IAP 
substrates are purified separately and studied for 
biological and immunochemical properties. 
2. MATERIALS AND METHODS 
2.1. Purification of IAP substrates from porcine 
brain membranes 
The procedures employed to purify three IAP 
substrates from porcine brain membranes are 
based on the methods developed to purify Gi and 
G, from rat brain [6] with the following modifica- 
tion. After the three chromatographies with 
DEAE-Sephacel, Ultrogel AcA-34 and DEAE- 
Toyopearl65O(S), an aliquot (15 nmol) of the frac- 
tions containing IAP substrate activity was diluted 
with 4 vols Tris-HCl (pH 8.0)/l mM NaEDTA/ 
1 mM dithiothreitol (TED) containing 0.7% 
3- [(3 -cholamidopropyl)dimethylammonio] - 1 -pro- 
panesulfonate (Chaps) and then applied to a Mono 
Q HR5/5 column which had been equilibrated 
with TED/0.7% Chaps/l25 mM NaCl. The col- 
umn was washed and eluted at a flow rate of 
1 ml/min with the following series of NaCl gra- 
dients using a Pharmacia FPLC system; 125 mM 
for 5 min; 125-250 mM over 30 min; 
250-1000 mM over 5 min. The eluate was col- 
lected in fractions of 1 ml. Fig.lA details the ac- 
tivities measured in the eluted fractions. This 
chromatography resulted in a partial separation of 
three peaks of IAP-substrate and guanosine 5 ‘-O- 
(thio)triphosphate (GTPyS)-binding activities; the 
first peak (I, fractions 13-15), second peak (II, 
fractions 17-19) and third minor peak (III, frac- 
tions 20-22). Each peak was diluted with an equal 
volume of TED/0.7% Chaps and further purified 
by rechromatography on the Mono Q column 
under the same conditions. Thus, three IAP 
substrates were purified to almost homogeneity 
(fig.lB). Resolution of each IAP substrate to 
GTPyS-bound cy- and fly-subunits was performed 
by high-performance gel filtration using a 
TSK-3000 SW column as in [14]. The polypeptide 
composition of the purified proteins was analyzed 
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Fig.1. Mono Q chromatography of IAP substrate 
proteins from porcine brain membranes. (A) IAP 
substrate-rich fractions were applied to Mono Q and 
eluted as described in section 2. Aliquots (10 ~1) of 
fractions were assayed for IAP-substrate (0) and 35S- 
labeled GTPyS-binding (A) activities. The absorbance at 
280 nm of the eluted protein was also monitored (-). 
(B) Each peak (I, II and III in A) from the Mono Q was 
further purified by rechromatography on Mono Q under 
the same conditions. 
by SDS-polyacrylamide gel electrophoresis and is 
shown in fig.2. 
2.2. Assay of activities 
IAP substrate protein was identified by its 
abilities to be “P-labeled, ADP-ribosylation in the 
presence of IAP and 32P-labeled NAD and to bind 
35S-labeled GTPyS as in [6,14]. Electrophoresis of 
polypeptides through SDS-polyacrylamide gels 
and the treatment of the samples with N- 
ethylmaleimide are described in [3,6]. Adenylate 
cyclase activity of human platelet membranes was 
estimated as in [6,15]. 
2.3. Preparation of affinity-purified antibodies 
against CY- and &subunits of IAP substrates 
and immunoblot procedures 
Three groups (each consisting of one or two) of 
rabbits were injected intradermally with purified 
rat brain ai, cy,, or ,By in Freund’s complete adju- 
vant (2 ml, lOO-2OOpg protein per animal), 
followed by three injections with half as much an- 
tigens and at intervals of 2-3 weeks. Animals were 
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Fig.2. SDS-polyacrylamide gel electrophoresis of IAP 
substrates purified from porcine brain membranes. 
Proteins were subjected to SDS-polyacrylamide gel 
(10% for A and 15% for B) electrophoresis and stained 
with either Coomassie blue (A) or silver (B) as described 
in section 2. Lanes: (1,2,3) peak I, II and III in fig.lB, 
respectively (1 pg for A and 0.2 pg for B); (4,5,6) cy- 
subunits resolved from peak I, II and III, respectively 
(0.2 pg for A and 0.1 pg for B); (7,8,9) &subunits 
resolved from peak I, II and III, respectively (0.2 pg for 
A and 0.1 pg for B). 
bled 2 weeks after the final injection. For affinity 
purification of antisera, l-2 mg purified ai, a0 or 
fly from rat brain was coupled to activated CH- 
Sepharose 4B (Pharmacia) to a final concentration 
of -0.5 mg protein per ml gel. Each whole serum 
or the 40% (NH&S04_precipitated fraction was 
passed through the cognate subunit-immobilized 
Sepharose, and after extensive washing with 0.1 M 
NaHC03/0.5 M NaCl (pH 8.3), specifically bound 
antibodies were eluted with 0.2 M glycine-HCl (pH 
2.5). The eluate was immediately adjusted to pH 
7-8 and filtered through Sephadex G-25 (fine) in 
phosphate-buffered saline containing 0.05% 
NaNs. Immunoblot analysis is described in [16]. 
2.4. Tryptic digestion of 32P-labeled ADP- 
ribosylated IAP substrates 
Three IAP substrates purified from porcine 
brain were incubated at 30°C for 30 min in a reac- 
tion mixture containing IAP and 32P-labeled NAD 
(5000 cpm/pmol) as in [6]. After the incubation, 
aliquots (500~1) of the mixture were filtered 
through a 10 ml column of Sephadex G-25 (fine) in 
TED/O.OS% Lubrol-PX. The radiolabeled IAP 
substrates (approx. 20pg/ml), which emerged in 
the void volume from the columns, were digested 
at 30°C with 2pg/ml of tosylphenylalanyl 
chloromethyl ketone-treated fl-trypsin in the above 
buffer. At the indicated times, aliquots (25 ~1) of 
the reaction mixture were removed and mixed with 
5 ~1 soybean trypsin inhibitor (50 pg/ml) contain- 
ing 10% SDS. The samples were treated with N- 
ethylmaleimide [3] and subjected. to SDS- 
polyacrylamide gel electrophoresis and autoradio- 
graphy. 
3. RESULTS AND DISCUSSION 
In [6], we purified two a@y-trimeric proteins (Gi 
and G,) with IAP-substrate and GTPyS-binding 
activities from rat brain membranes. They differed 
from each other in LY only; the molecular mass of 
the two (Y was 41 kDa (ai) and 39 kDa (aO) and Lyi 
could inhibit the adenylate cyclase catalyst, 
whereas a0 could not [ 141. In the course of further 
studies, however, we found that IAP substrates in 
brain tissues were more heterogeneous. There were 
three peaks of IAP-substrate and GTPyS-binding 
activities after Mono Q column chromatography 
of IAP substrate-rich fractions from porcine brain 
membranes (fig.1). Thus, we obtained three &y- 
heterotrimeric IAP substrate proteins (fig.2). 
These heterogeneous IAP substrates are referred to 
as ~yqlpy, cu&y and c~_$y, respectively, based on 
the molecular masses of their a-subunits. The three 
c~ were the target of IAP-catalyzed ADP- 
ribosylation (see figs 3,4) and contained the sites of 
GTPyS binding (see fig.5). The order of the con- 
tents of these proteins was CYU~&Y > ~u4tcy > cy4&y 
in a number of preparations from porcine and rat 
(not shown) brain membranes. 
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Fig.3. Cross-reaction of porcine brain IAP substrates with affinity-puri~ed antibodies specific for the cy and fly of rat 
brain IAP substrates. Three IAP substrates (1 pg) purified from porcine brain were subjected to SDS-polyacrylamide 
gel (10%) electrophoresis and analyzed for immunoblot as described in section 2. Lanes: (1,2,3) peak I (0(4fiy), II 
(o&y) and III (o&y) in fig.lB, respectiveIy. (A) Coomassie blue-stained gels, (B) anti-rat ai antibody, (C) anti-rat 
LY~ antibody, (D) anti-rat & antibody, (E) 3LP-labeled ADP-ribosylated cy. 
As shown in fig.3, antibody raised against rat 
brain CYI (anti-& reacted with the a41 of porcine 
brain LYE&. On the other hand, antibody raised 
against rat brain a, (anti-a,) reacted with the ~~39 
of porcine brain LY&. Thus, the W&T and a&y 
purified in the present study are the same entities 
as Gi and G,, respectively, purified from rat brain 
[6]. However, the porcine brain CU~Q@ was a new 
IAP substrate protein different from G, or G,, 
since neither anti+ nor ant&, cross-reacted with 
the ~~40. Antibody raised against rat brain fly 
reacted with all the fl (36135 kDa doublet) of the 
porcine brain IAP substrates, suggesting that the P 
of the three IAP substrates are the same polypep- 
tide or at least share a common antigenic deter- 
minant(s). 
Differences among the three a of porcine brain 
IAP substrates were further supported by the 
results of the limited tryptic digestion of 
[32P]ADP-ribosylated IAP substrates (fig.4). The 
limited fragmentation patterns of the cy in the 
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presence of 20pM AlC13, 6 mM MgClz and 
10 mM NaF (AMF) were quite different from 
those in its absence, confirming our previous 
results that there was a conformational change in 
cy in the presence of AMF [6]. The 32P-labeled 
ADP-ribose of the three cy was transferred ex- 
clusively to the 38-37 kDa fragment when the 
radiolabeled IAP substrates were digested in the 
presence of AMF (fig.4B). In the absence of AMF, 
the majority of the radioactive ADP-ribose was 
located in the 17-15 kDa fragment (fig.4A). The 
proteolytic fragments containing ADP-ribose aris- 
ing from the three a! were not identical to one 
another, although there was a general similarity of 
the fragmentation patterns among the three a in 
the presence or absence of AMF. 
Fig.5 shows the effects of the porcine brain IAP 
substrates and their constituent subunits on the 
adenylate cyclase activity of human platelet mem- 
branes. All of the three GTPyS-bound IAP 
substrates were potent inhibitors of the adenylate 
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Fig.4. Limited tryptic digestion of ADP-ribosylated 
porcine brain IAP substrates. Three IAP substrates 
purified from porcine brain were “P-labeled ADP- 
ribosylated and then digested with trypsin in the 
presence (B) or absence (A) of AMF as described in 
section 2. At the indicated times, aliquots of the 
digestion mixture were removed and subjected to SDS- 
polyacrylamide gel (15% for A and 10% for B) 
electrophoresis and autoradiography. Lanes: 
(1,4,7,10,13) peak I (a4&) in fig.lB; (2,5,8,11,14) peak 
II (cu&~) in fig.lB; (3,6,9,12,15) peak III (~$7) in 
fig.lB; DF, dye front. 
cyclase (fig.SA). Differences were noted, however, 
in that the inhibition caused by GTPyS-bound 
cy3& or cu4& appeared to be saturable at 20 nM 
(2 pmol/assay tube), while the inhibitory action of 
CQ& was more potent; the degree of the inhibition 
by GTPyS-bound adt,8y was apparently larger 
than that by GTPyS-bound as&y or o&y. In 
previous papers [6,14,15], we have shown that the 
incubation of Gi (or G,) with GTPyS results in 
dissociation into GTPyS-bound LY and fly, 
Therefore, the effects of GTPyS-bound a and fiy 
resolved from each porcine brain IAP substrates 
were further examined. The fly resolved from 
Fig.5. Effects of porcine brain IAP substrates and their 
constituent LY- and &subunits on the adenylate cyclase 
activity of human platelet membranes. (A) The three 
IAP substrates (1OOpg) were incubated at 30°C for 
60 min in 500~1 TED/0.7% Chaps/25 mM MgCls 
35 containing 5 pM S- labeled GTPrS (1000 cpm/pmol) 
and then filtered through a 10 ml column of Sephadex 
G-25 in TED (with 0.1 mM EDTA)/l mM MgC12/0.7% 
Chaps. lo-p1 aliquots of the GTPyS-bound IAP 
substrates, which emerged in the void volume from the 
column, were incubated at 30°C for 30 min with 90 pl of 
a reaction mixture containing 3Opg of human platelet 
membranes and 10 gM forskolin. The adenylate cyclase , 
activities were assayed as described in section 2. (B) The 
GTPyS-bound cy and fly were obtained from each IAP 
substrate as described in section 2 and assayed for 
adenylate cyclase activity as in A. The values are 
expressed as percentages of the control value obtained 
without purified proteins (10 ,~l of a buffer solution used 
for the G-25 or TSK column elution), which was 420 and 
405 pmol CAMP formed/tube for A and B, respectively. 
cy4& or cu3Spr was a potent inhibitor of the cyclase 
(fig.SB), confirming the previous results [6]. The 
fly resolved from the new IAP substrate, CL&~, 
also inhibited the cyclase activity in a fashion 
similar to that from a4@y or ,~~s&y. In contrast to 
the action of fly, only the GTPyS-bound ~~41 effec- 
tively inhibited the cyclase activity. However, the 
inhibition by the ~41 did not saturate at 25 nM; this 
species inhibited adenylate cyclase with lower ap- 
parent affinity than did the resolved fly. Slight in- 
hibition caused by high concentrations of 
GTPyS-bound ~~39 or cy40 would be explained by 
contamination of these preparations with a few 
percent of Py. 
In this report, we have purified three IAP 
substrates from porcine brain membranes. One of 
them, a&y, was a novel IAP substrate protein; 
the cy&y differed from Gi(a4$y) or G, (as&y) in 
357 
Volume 213, number 2 FEBS LETTERS March 1987 
the (Y only, based on the following observations. (i) 
The electrophoretic mobilities through SDS- 
polyacrylamide gels among the three LY were not 
identical to one another either before or after IAP- 
catalyzed ADP-ribosylation (figs 2,3). (ii) Limited 
proteolysis of the ADP-ribosylated cy with trypsin 
yielded product formation which were different 
between a40 and cyqr or ~~39 (fig.4). (iii) No cross- 
reaction was observed between cy40 and the 
affinity-purified antibodies raised against mi or e0 
(fig.3). (iv) Only GTPyS-bound 1~41 could effec- 
tively inhibit membrane-bound adenylate cyclase, 
whereas GTP~S-bound cy40 or ~~39 could not 
(fig.SB). (v) The fly resolved from the three IAP 
substrates inhibited the adenylate cyclase in a 
fashion similar to one another (fig.SB). (vi) The 
three ,& were recognized by affinity-purified an- 
tibody raised against the fly of rat brain IAP 
substrates (fig.3). 
What is the physiological role of the new IAP 
substrates (m&7)? Sincefly seems to be an impor- 
tant component responsible for adenylate cyclase 
inhibition, CQ& must be as good a communicator 
as Gi and G, in receptor-linked inhibition of the 
cyclase. Nevertheless, it is tempting to speculate 
that ~~40 (and a39) iscapable of interacting with an 
enzyme system other than adenylate cyclase, since 
recent studies have revealed that prior exposure of 
cells to IAP prevents the cell responses to receptor 
stimulation in a CAMP-independent manner (see 
section 1). 
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